TEXAS Health and Human Services | Texas Department of State Health Services

January 27, 2023

Dear Therapeutic Provider:

Effective immediately, **Evusheld** (tixagevimab co-packaged with cilgavimab) **is no longer authorized for use in the United States.** Data show that Evusheld is unlikely to be active against more than 90% SARS-CoV-2 variants that are currently circulating, according to the most recent CDC COVID data tracker: Variant Proportions . This means that Evusheld is not expected to provide protection against developing COVID-19 if a person is exposed to those variants. The FDA updated the Letter of Authorization for Evusheld on January 26, 2023. HHS and AstraZeneca have paused distribution of Evusheld until further notice.

The U.S. Government recommends that facilities and providers with Evusheld retain all product in the event that SARS-CoV-2 variants which are neutralized by Evusheld become more prevalent in the U.S. in the future. Retained product must be appropriately held in accordance with storage conditions detailed in the Fact Sheet authorized for Health Care Providers and the Letter of Authorization.

Please visit the FDA's website and view ASPR's information sheet for additional details. You may also contact ASPR at COVID19Therapeutics@hhs.gov should you have questions

There are several other therapies – Paxlovid (nirmatrelvir with ritonavir), Veklury (remdesivir), and Lagevrio (molnupiravir) – that are expected to be effective against current SARS-CoV2 sub-variants, and that are authorized or approved to treat certain patients with mild-to-moderate COVID-19 who are at high risk for progression to severe disease, including hospitalization or death. In addition, COVID-19 Convalescent Plasma is authorized for use in patients who are immunocompromised. Health care providers should assess whether these treatments are right for their patients and can refer to the recently-updated NIH Guidelines for Therapeutic Management of Nonhospitalized Adults With COVID-19. Please see the US HHS Therapeutic locator for locations with these medications.

Please request Paxlovid or Lagevrio on the HPOP Provider Portal or email therapeutics@dshs.texas.gov to sign up for the Oral Antivirals if your facility has a valid Texas Pharmacy License. Make sure your reporting of administered and on-hand therapeutics is current.

You may wish to purchase Veklury (remdesivir) for patients who are unable to take one of the oral antiviral medications. Hospitals can purchase Veklury through multiple distributors through the facility's normal procurement processes (Gilead Resource Call Center at 1-800-226-

2056). Non-hospitals can purchase from AmerisourceBergen (Outpatient Product Information Guide including ordering).

For information on Convalescent Plasma, please visit Convalescent Plasma EUA HCP Fact Sheet.

Visit DSHS Information for COVID-19 Therapeutics for current information.